{"version":"2026.03.01","generated_at":"2026-03-01T04:57:46.830065+00:00","total":21,"minisearch_fields":["title","text","tags"],"minisearch_store_fields":["source_id","category","date","url","title"],"entries":[{"id":"ata_2023_thyroid_c0000","title":"ATA 2023 Thyroid Guidelines (Part 1)","text":"Home Professionals Events  Education ATA Publications ATA Guidelines  Statements Research Grants Thyroid Cancer Patient Information Trainees Corner Corporate Leadership Council ATA Career Center Laboratory Education Scientific  Professional Interest THYROID Calculators Thyroid Cancer Staging Calculator (CEA) Doubling Time Calculator Change In Thyroid Nodule Volume Calculator Patients Thyroid Patient Information Find an Endocrinology – Thyroid Specialist Patient Support Links Clinical Thyroidology for the Public Friends of the ATA Newsletter ATA Practice Guidelines Clinical Trials ATA Research Accomplishments Members Member Benefits Become an ATA Member Renew Your Membership Member Guidelines","tags":"thyroid TSH T4 T3 hypothyroid Graves Hashimoto","source_id":"ata_2023_thyroid","category":"guideline","date":"2026-03","url":"https://www.thyroid.org/thyroid-professionals/clinical-thyroidology/"},{"id":"ata_2023_thyroid_c0001","title":"ATA 2023 Thyroid Guidelines (Part 2)","text":"Leung, MD, MSc CLINICAL THYROIDOLOGY, this highly valued publication provides concise reviews of the most impactful articles in the clinical thyroid literature currently. Experts in the field summarize the most cutting-edge, relevant articles that clinicians should know about and provide insight into the significance of each article as it relates to clinical thyroid practice. Please send editorial questions to clinicalthyroidology@thyroid.","tags":"thyroid TSH T4 T3 hypothyroid Graves Hashimoto","source_id":"ata_2023_thyroid","category":"guideline","date":"2026-03","url":"https://www.thyroid.org/thyroid-professionals/clinical-thyroidology/"},{"id":"ata_2023_thyroid_c0002","title":"ATA 2023 Thyroid Guidelines (Part 3)","text":"org Search Clinical Thyroidology CURRENT ISSUE Member Access to Full Articles Clinical Thyroidology Archive Volume 25, Issue 12, December 2013 Table of Contents Volume 25, Issue 11, November 2013 Table of Contents Volume 25, Issue 10, October 2013 Table of Contents Volume 25, Issue 9, September 2013 Table of Contents Volume 25, Issue 8, August 2013 Table of Contents Volume 25, Issue 7, July 2013 Table of Contents Volume 25, Issue 6, June 2013 Table of Contents Volume 25, Issue 5, May 2013 Table of Contents Volume 25, Issue 4, April 2013 Table of Contents Volume 25, Issue 3, March 2013 Table of Contents Volume 25, Issue 2, February 2013 Table of Contents Volume 25, Issue 1, January 2013 Table","tags":"thyroid TSH T4 T3 hypothyroid Graves Hashimoto","source_id":"ata_2023_thyroid","category":"guideline","date":"2026-03","url":"https://www.thyroid.org/thyroid-professionals/clinical-thyroidology/"},{"id":"ata_2023_thyroid_c0003","title":"ATA 2023 Thyroid Guidelines (Part 4)","text":"42 MB) Volume 20, Issue 1, February 2008 (PDF File, 896 KB) Volume 19, Issue 3, November 2007 (PDF File, 344 KB) Volume 19, Issue 2, July 2007 (PDF File, 464 KB) Volume 19, Issue 1, March 2007 (PDF File, 283 KB) Volume 18, Issue 3, November 2006(PDF File, 386 KB) Volume 18, Issue 2, July 2006(PDF File, 1. 3 MB) Volume 18, Issue 1, March 2006 (PDF File, 1.","tags":"thyroid TSH T4 T3 hypothyroid Graves Hashimoto","source_id":"ata_2023_thyroid","category":"guideline","date":"2026-03","url":"https://www.thyroid.org/thyroid-professionals/clinical-thyroidology/"},{"id":"ata_2023_thyroid_c0004","title":"ATA 2023 Thyroid Guidelines (Part 5)","text":"4 MB) Volume 17 Issue 3, November 2005 (PDF File 616 KB) Volume 17, Issue 2, July 2005 (PDF File, 393 KB) Volume 17, Issue 1, March 2005 (PDF File, 396KB) Volume 16, Issue 3, November 2004 (PDF File, 261KB) Volume 16, Issue 2, July 2004 (PDF File, 463KB) Volume 16, Issue 1, March 2004 (PDF File, 436 KB) Volume 15, Issue 3, November 2003 (PDF File, 407 KB) Volume 15, Issue 2, July 2003 (PDF File, 469 KB) Volume 15, Issue 1, March 2003 (PDF File, 42 KB) Volume 14, Issue 3, November 2002 (PDF File, 397 KB) Volume 14, Issue 2, July 2002 (PDF File, 397 KB) Volume 14, Issue 1, March 2002 (PDF File, 377 KB) Volume 13, Issue 3, November 2001 (PDF File,634 KB) Volume 13, Issue 2, July 2001 (PDF File,","tags":"thyroid TSH T4 T3 hypothyroid Graves Hashimoto","source_id":"ata_2023_thyroid","category":"guideline","date":"2026-03","url":"https://www.thyroid.org/thyroid-professionals/clinical-thyroidology/"},{"id":"ata_2023_thyroid_c0005","title":"ATA 2023 Thyroid Guidelines (Part 6)","text":"S. Patent and Trademark Office as trademarks of the American Thyroid Association , Inc. 2026 American Thyroid Association.","tags":"thyroid TSH T4 T3 hypothyroid Graves Hashimoto","source_id":"ata_2023_thyroid","category":"guideline","date":"2026-03","url":"https://www.thyroid.org/thyroid-professionals/clinical-thyroidology/"},{"id":"kdigo_2017_bone_c0000","title":"KDIGO 2017 CKD-MBD Guideline (Part 1)","text":"Back CKD-Mineral and Bone Disorder (CKD-MBD) The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD) represents a selective update of the prior guideline published in 2009. This update, along with the 2009 publication, is intended to assist the practitioner caring for adults and children with CKD, those on chronic dialysis therapy, or individuals with a kidney transplant. Specifically, the topic areas for which updated recommendations are issued include diagnosis of bone abnormalities in CKD-MBD; treatment of CKD-MBD by targeting phospha","tags":"CKD bone PTH calcium phosphorus vitamin_D","source_id":"kdigo_2017_bone","category":"guideline","date":"2026-03","url":"https://kdigo.org/guidelines/ckd-mbd/"},{"id":"kdigo_2017_bone_c0001","title":"KDIGO 2017 CKD-MBD Guideline (Part 2)","text":"Limitations of the evidence are discussed, with areas of future research also presented. The guideline was co-chaired by Markus Ketteler, MD, FERA (Klinikum Coburg, Germany) and Mary Leonard, MD, MSCE (Stanford University School of Medicine, United States).","tags":"CKD bone PTH calcium phosphorus vitamin_D","source_id":"kdigo_2017_bone","category":"guideline","date":"2026-03","url":"https://kdigo.org/guidelines/ckd-mbd/"},{"id":"kdigo_2017_bone_c0002","title":"KDIGO 2017 CKD-MBD Guideline (Part 3)","text":"Guideline Suite 2017 CKD-MBD Guideline Update 2017 CKD-MBD Guideline Update Executive Summary 2017 CKD-MBD Guideline Update Synopsis 2017 CKD-MBD Guideline Update Appendix A  B 2017 CKD-MBD Guideline Update Evidence Summary Tables 2017 CKD-MBD Guideline Update Speaker's Guide (PDF) 2017 CKD-MBD Guideline Update Speaker's Guide (PPT) 2009 CKD-MBD Guideline 2009 CKD-MBD Guideline Supplementary Tables Guideline Resources IMPLEMENTATION TOOLS KDIGO Quick Reference Guide CKD-MBD Update: Visual Guidelines Translating Evidence Into Practice Video Management of Hyperphosphataemia in CKD MBD Video 2017 CKD-MBD Guideline Update Quick Reference Guide Summary of 2017 CKD-MBD Guideline Update Recommendat","tags":"CKD bone PTH calcium phosphorus vitamin_D","source_id":"kdigo_2017_bone","category":"guideline","date":"2026-03","url":"https://kdigo.org/guidelines/ckd-mbd/"},{"id":"kdigo_2017_bone_c0003","title":"KDIGO 2017 CKD-MBD Guideline (Part 4)","text":"Translations 2017 CKD-MBD Guideline Update Translations Chinese (Mandarin) 2017 KDIGO 临床实践指南更新 慢性肾脏病-矿物质与骨异常 (CKD-MBD) 诊断, 评估, 预防和治疗 French Résumé des recommandations KDIGO 2017 révisées sur la prise en charge des troubles minéraux et osseux associés aux maladies rénales chroniques (TMO-MRC): quels sont les changements et pourquoi sont-ils importants? German Update 2017 der KDIGO-Leitlinie zu den Störungen des Mineralund Knochenhaushalts bei chronischer Nierenerkrankung Japanese KDIGO 2017 CKD-MBD推奨文和訳版 Korean (Executive Summary) 2017년 KDIGO 만성 콩팥병-미네랄뼈질환 가이드라인 업데이트: 변경 사항과 주요 시사점 Turkish (Executive Summary) Böbrek Hastalıkları: KDIGO Kronik Böbrek Hastalıgı-Mineral ve Kemik Bozuklukları (KB","tags":"CKD bone PTH calcium phosphorus vitamin_D","source_id":"kdigo_2017_bone","category":"guideline","date":"2026-03","url":"https://kdigo.org/guidelines/ckd-mbd/"},{"id":"kdigo_2017_bone_c0004","title":"KDIGO 2017 CKD-MBD Guideline (Part 5)","text":"والعظم – الناتج عن الداء الكلوي المزمن Chinese (Mandarin) KDIGO 慢性肾脏病矿物质和骨异常诊断、评价、预防和治疗的临床实践指南 French RECOMMANDATIONS KDIGO DE BONNES PRATIQUES CLINIQUESPOUR LE DIAGNOSTIC, LEVALUATION, LA PREVENTION ET LE TRAITEMENT DES TROUBLES MINERAUX ET OSSEUX ASSOCIES AUX MALADIES RENALES CHRONIQUES (TMO-MRC) German KDIGO-Leitlinien zu den Störungen des Mineral- und Knochenhaushalts bei chronischer Nierenerkrankung (Part 1) KDIGO-Leitlinien zu den Störungen des Mineral- und Knochenhaushalts bei chronischer Nierenerkrankung (Part 2) Greek ΚΑΤΕΥΘΥΝΤΗΡΙΕΣ ΟΔΗΓΙΕΣ ΤΗΣ ΟΡΓΑΝΩΣΗΣ KDIGO ΓΙΑ ΤΗ ΔΙΑΓΝΩΣΗ, ΤΗΝ ΕΚΤΙΜΗΣΗ, ΤΗΝ ΠΡΟΛΗΨΗ ΚΑΙ ΤΗ ΘΕΡΑΠΕΙΑ ΤΗΣ ΔΙΑΤΑΡΑΧΗΣ ΤΟΥ ΜΕΤΑΒΟΛΙΣΜΟΥ ΤΩΝ ΟΣΤΩΝ ΚΑΙ ΤΩΝ ΜΕΤΑΛΛΙΚΩΝ ΣΤΟΙ","tags":"CKD bone PTH calcium phosphorus vitamin_D","source_id":"kdigo_2017_bone","category":"guideline","date":"2026-03","url":"https://kdigo.org/guidelines/ckd-mbd/"},{"id":"kdigo_2017_bone_c0005","title":"KDIGO 2017 CKD-MBD Guideline (Part 6)","text":"The recommendations are designed to provide information and assist decision-making. They are not intended to define a standard of care, and should not be construed as one. Neither should they be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health care professional making use of this Guideline is responsible for evaluating the appropriateness of applying them in the setting of any particular clinical situation. The recommendations for research contained within","tags":"CKD bone PTH calcium phosphorus vitamin_D","source_id":"kdigo_2017_bone","category":"guideline","date":"2026-03","url":"https://kdigo.org/guidelines/ckd-mbd/"},{"id":"kdigo_2024_ckd_c0000","title":"KDIGO 2024 CKD Evaluation and Management (Part 1)","text":"Back CKD Evaluation and Management The KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD), an update to the 2012 guideline, was published in March 2024 in Supplement to Kidney International. The Executive Summary was published in the April 2024 issue of Kidney International. The guideline, an update to the KDIGO 2012 CKD Guideline, was co-chaired by Professor Adeera Levin, MD (Canada) and Paul Stevens, MB (United Kingdom). The guideline is intended for healthcare professionals who provide kidney care, for people with suspected or diagnosed CKD and their caregivers, and for policymakers and commissioners of CKD services. The aim is to prov","tags":"CKD eGFR UACR proteinuria SGLT2i dialysis","source_id":"kdigo_2024_ckd","category":"guideline","date":"2026-03","url":"https://kdigo.org/guidelines/ckd-evaluation-and-management/"},{"id":"kdigo_2024_ckd_c0001","title":"KDIGO 2024 CKD Evaluation and Management (Part 2)","text":"Key highlights of the KDIGO CKD Guideline include guidance updates on the measurements of estimated glomerular filtration rate and albuminuria, utilization of CKD risk prediction equations, and personalized treatment recommendations for kidney and cardiovascular risk reductions tailored to individual patient needs and preferences. Treatment approaches and actionable guideline recommendations are based on systematic review of relevant studies and appraisal of the quality of the evidence and the strength of recommendations, following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. The guideline also provides practice points, which serve to direct clinic","tags":"CKD eGFR UACR proteinuria SGLT2i dialysis","source_id":"kdigo_2024_ckd","category":"guideline","date":"2026-03","url":"https://kdigo.org/guidelines/ckd-evaluation-and-management/"},{"id":"kdigo_2024_ckd_c0002","title":"KDIGO 2024 CKD Evaluation and Management (Part 3)","text":"Guideline Suite KDIGO 2024 CKD Guideline KDIGO 2024 CKD Guideline Executive Summary KDIGO 2024 CKD Guideline Data Supplement KDIGO 2024 CKD Guideline Slide Set KDIGO 2024 CKD Guideline Key Takeaways Slide Set KDIGO 2024 CKD Guideline Top 10 Takeaways for Nephrologists - Evaluation KDIGO 2024 CKD Guideline Top 10 Takeaways for Nephrologists - Management KDIGO 2024 CKD Guideline Top 12 Takeaways for Pediatricians KDIGO 2024 CKD Guideline Top 10 Takeaways for PCPs - Evaluation KDIGO 2024 CKD Guideline Top 10 Takeaways for PCPs - Management KDIGO 2024 CKD Guideline Top Takeaways - People Living with CKD Guideline Resources KDIGO DIGITAL TOOLS KDIGO DIGITAL HEAT MAP KDIGO 2024 CKD GUIDELINE VIDEO","tags":"CKD eGFR UACR proteinuria SGLT2i dialysis","source_id":"kdigo_2024_ckd","category":"guideline","date":"2026-03","url":"https://kdigo.org/guidelines/ckd-evaluation-and-management/"},{"id":"mdcalc_index_c0000","title":"MDCalc — 臨床計算器清單 (Part 1)","text":"PopularNewestFavoritesSpecialtyGuidelinesAllCreatinine Clearance (Cockcroft-Gault Equation)Calculates CrCl according to the Cockcroft-Gault equation. CKD-EPI Equations for Glomerular Filtration Rate (GFR)Estimates GFR in CKD patients using serum creatinine, cystatin C, or both. Mean Arterial Pressure (MAP)Calculates mean arterial pressure. Wells' Criteria for Pulmonary EmbolismObjectifies risk of pulmonary embolism. MDRD GFR EquationEstimates GFR in CKD patients using creatinine and patient characteristics. CHA₂DS₂-VASc Score for Atrial Fibrillation Stroke RiskCalculates stroke risk for patients with atrial fibrillation. Calcium Correction for Hypoalbuminemia and HyperalbuminemiaCalculates a","tags":"calculator CHADS2 SOFA Framingham clinical_tools","source_id":"mdcalc_index","category":"tool","date":"2026-03","url":"https://www.mdcalc.com"},{"id":"mdcalc_index_c0001","title":"MDCalc — 臨床計算器清單 (Part 2)","text":"HEART Score for Major Cardiac EventsPredicts 6-week risk of major adverse cardiac events in patients with chest pain. Maintenance Fluids CalculationsCalculates maintenance fluid requirements by weight. ASCVD (Atherosclerotic Cardiovascular Disease) 2013 Risk Calculator from AHA/ACCDetermine 10-year risk of hard ASCVD, i. e. myocardial infarction, stroke, or death due to coronary heart disease or stroke. Glasgow Coma Scale (GCS)Coma severity based on Eye (4), Verbal (5), and Motor (6) criteria. Sodium Correction for HyperglycemiaCalculates the actual sodium level in patients with hyperglycemia. Wells' Criteria for DVTCalculates risk of DVT based on clinical criteria. PERC Rule for Pulmonary E","tags":"calculator CHADS2 SOFA Framingham clinical_tools","source_id":"mdcalc_index","category":"tool","date":"2026-03","url":"https://www.mdcalc.com"},{"id":"mdcalc_index_c0002","title":"MDCalc — 臨床計算器清單 (Part 3)","text":"LDL CalculatedCalculates LDL based on total and HDL cholesterol and triglycerides. Steroid Conversion CalculatorConverts steroid dosages using dosing equivalencies. HOMA-IR (Homeostatic Model Assessment for Insulin Resistance)Approximates insulin resistance. SIRS, Sepsis, and Septic Shock CriteriaDefines the severity of sepsis and septic shock. CURB-65 Score for Pneumonia SeverityEstimates mortality of community-acquired pneumonia to help determine inpatient vs. outpatient treatment. Fractional Excretion of Sodium (FENa)Determines if renal failure is due to prerenal or intrinsic pathology. Sequential Organ Failure Assessment (SOFA) ScorePredicts ICU mortality based on lab results and clinica","tags":"calculator CHADS2 SOFA Framingham clinical_tools","source_id":"mdcalc_index","category":"tool","date":"2026-03","url":"https://www.mdcalc.com"},{"id":"mdcalc_index_c0003","title":"MDCalc — 臨床計算器清單 (Part 4)","text":"HAS-BLED Score for Major Bleeding RiskEstimates risk of major bleeding for patients on anticoagulation to assess risk-benefit in atrial fibrillation care. MELD Na (UNOS/OPTN)Quantifies end-stage liver disease for transplant planning with sodium. Glasgow-Blatchford Bleeding Score (GBS)Stratifies upper GI bleeding patients who are \"low-risk\" and candidates for outpatient management. CIWA-Ar for Alcohol WithdrawalThe CIWA-Ar objectifies severity of alcohol withdrawal. GRACE ACS Risk and Mortality CalculatorEstimates admission to 6 month mortality for patients with acute coronary syndrome. ABCD² Score for TIAEstimates the risk of stroke after a suspected transient ischemic attack (TIA). Padua Pr","tags":"calculator CHADS2 SOFA Framingham clinical_tools","source_id":"mdcalc_index","category":"tool","date":"2026-03","url":"https://www.mdcalc.com"},{"id":"tla_2024_lipid_c0000","title":"台灣脂質學會 2024 血脂異常治療指引 (Part 1)","text":"Taiwan Laryngological Association 台灣喉科醫學會 Breath better, eat better sleep better, today. TALC2025 TALC 2025 Announcement The 3rd Annual Meeting and International Symposium of the Taiwan Laryngological Society (TALC, Taiwan Autumn Laryngology Conference) has successfully concluded. We sincerely thank all our members for their enthusiastic participation! 第三屆台灣喉科醫學會年會暨國際學術研討會順利成功，感謝您的熱情參與與支持 大會花絮、感言 台灣喉科醫學會 第二屆理監事改選於2025年9月13日順利舉行，當選名單：  理事長方端仁 常務理事朱本元、楊宗霖 理事朱永祥、徐正明、莊俊義、辛立仁、黃子晏、蔡青劭、許巍鐘、鄒永恩 候補理事黃澤人 常務監事王誌群 監事曹傑漢、蘇性豪 秘書處秘書長：盧怡安副秘書長：曾文萱秘書：林麗芸 大會官網: https://www. talc2025. com. tw 最新活動 台灣喉科醫學會網站贊助商募集中 2026 台灣喉科醫學會春季學術研討會 2026/3/21（六） 13:30–17:00 台中林酒店 7F 柏林廳 報名連結：https://reurl.","tags":"高血脂 LDL statin PCSK9i 台灣指引","source_id":"tla_2024_lipid","category":"society","date":"2026-03","url":"https://www.tla.org.tw/"},{"id":"tla_2024_lipid_c0001","title":"台灣脂質學會 2024 血脂異常治療指引 (Part 2)","text":"cc/la4eQj歡迎同道先進踴躍報名參加 學會近期活動 2025 TALC第三屆台灣喉科醫學會 年會暨國際學術研討會 2025年9月13日（六） 高雄萬豪酒店1 中國醫藥大學與台灣喉科醫學會合辦 台灣中區喉部手術研討會 2025年8月3日 地點：台中日月千禧酒店 彰化基督教醫院與台灣喉科醫學會合辦 探索音聲的奧秘-喉科與嗓音治療專題 2025年8月9日 地點：彰化基督教醫院蘭 contact us 喉科醫學會 關於本學會 秘書處03-3281200 #3971","tags":"高血脂 LDL statin PCSK9i 台灣指引","source_id":"tla_2024_lipid","category":"society","date":"2026-03","url":"https://www.tla.org.tw/"}]}